Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety-Reference-Cited by-同舟云学术

Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety

Published:2007-04 Issue:4 Volume:56 Page:604-611
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Lowe Nicholas J.,Glaser Dee Anna,Eadie Nina,Daggett Simon,Kowalski Jonathan W.,Lai Pan-Yu

Publisher

Elsevier BV

Subject

Dermatology

Reference29 articles.

1. Multi-Specialty Working Group on the Recognition, Diagnosis, and Treatment of Primary Focal Hyperhidrosis. Recognition, diagnosis, and treatment of primary focal hyperhidrosis;Hornberger;J Am Acad Dermatol,2004

2. Hyperhidrosis: a review of current management;Atkins;Plast Reconstr Surg,2002

3. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial;Naumann;Br J Dermatol,2002

4. Prospective open-label study of botulinum toxin type A in patients with primary axillary hyperhidrosis: effects on functional impairment and quality of life;Solish;Dermatol Surg,2005

5. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey;Strutton;J Am Acad Dermatol,2004

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Botulinum Toxin for the Treatment of Postmenopausal Craniofacial Hyperhidrosis;Cureus;2024-09-01

2. Treatment of Primary Axillary Hyperhidrosis with Two Doses of Botulinum Toxin A—Observational Study;Toxins;2024-07-16

3. Dermatologic Conditions Following Limb Loss;Physical Medicine and Rehabilitation Clinics of North America;2024-07

4. Update on Non-Interchangeability of Botulinum Neurotoxin Products;Toxins;2024-06-10

5. Using Neuromodulators for Salivary, Eccrine, and Apocrine Gland Disorders;Dermatologic Surgery;2024-06-07